Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ardent Health, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements about accounts receivable and revenue recognition [2][4]. Group 1: Allegations and Financial Impact - The complaint alleges that Ardent Health and its executives made false and misleading statements regarding the company's accounts receivable and the processes used to determine their collectability [4]. - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue, attributed to revised assessments of accounts receivable collectability following a transition to a new revenue accounting system [4]. - The new accounting system, Kodiak RCA, allowed for more precise evaluations of accounts receivable, leading to earlier recognition of reserves compared to the previous framework [4]. - Ardent Health also reduced its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $625 million to $530 million - $555 million, citing persistent industry-wide cost pressures [4]. - Following this announcement, Ardent Health's stock price fell by $4.75 per share, nearly 34%, from $14.05 to $9.30 on November 13, 2025, amid unusually high trading volume [4]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased or acquired securities in Ardent between July 18, 2024, and November 12, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][2]. - There is a deadline of March 9, 2026, for investors to seek the role of lead plaintiff in the federal securities class action filed against Ardent [2][5]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [5].
ARDT 48 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ardent Health (ARDT) Investors of Securities Class Action Deadline on March 9, 2026